$EOLS News

Evolus to Report Third Quarter Financial Results on November 4, 2026

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As Misleading

Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

Evolus Inc (NASDAQ:EOLS) Passes Minervini Trend Template and High Growth Momentum Screen

Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Evolus: The Injectable Platform Is Becoming The Real Moat

Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation

Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ...

Evolus Q2 Earnings Call Highlights

Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7%

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate

Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est